Article date: July 2012
By: Andrew G Polson, Reina N Fuji in Volume 166, Issue 5, pages 1600-1602
To improve drug development outcomes, it is important to review when preclinical pharmacodynamic and safety models have successfully predicted human responses and when they have not. In a recent issue of the BJP, Bugelski and Martin examined the concordance between preclinical and human data for biopharmaceuticals targeted to cell‐surface proteins. The cases are interesting and several trends emerge. The pharmacodynamics of biopharmaceuticals in non‐human primates is largely predictive; the use of surrogates in rodents may be similarly predictive, allowing for more conservative use of non‐human primates. While overall concordance of preclinical toxicology data and clinical safety was poor, this is largely a reflection of the immunomodulatory biology of the majority of the biopharmaceuticals evaluated. The examples show that adverse effects in animals that were the result of direct and/or exaggerated pharmacology were modelled well, but that specific infections or other indirect outcomes of immunomodulation, along with cytokine‐related events, were not modelled well in preclinical studies.
LINKED ARTICLES
To view Bugelski and Martin visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01811.x and to view Martin and Bugelski visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01812.x
DOI: 10.1111/j.1476-5381.2012.01916.x
View this article